Overexpression of β-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 1, 2014, Pages 264-271

  Wang, Hai ^a   Wang, Haiyan ^a   Makki, Mohammad Shahidul ^b   Wen, Juanjuan ^a   Dai, Yingqing ^a   Shi, Qunli ^a   Liu, Qi ^a   Zhou, Xiaojun ^a   Wang, Jiandong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b Northeast Ohio Medical University   (United States)

Author keywords

Catenin; CyclinD1; Ovarian serous carcinoma; Prognosis

Indexed keywords

BETA CATENIN; CCND1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; CYCLIN D1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER STAGING; CYCLIND1; CYSTADENOCARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; OVARIAN SEROUS CARCINOMA; OVARY TUMOR; PATHOLOGY; PROGNOSIS; UPREGULATION; YOUNG ADULT; Β-CATENIN;

CYCLIND1; OVARIAN SEROUS CARCINOMA; PROGNOSIS; Β-CATENIN;

ADULT; AGED; BETA CATENIN; CYCLIN D1; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 84891767337     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S. Carcinoma of the ovary. Int J Gynaecol Obstet 2003; 83 Suppl 1: 135-66.
3. Itami A, Shimada Y, Watanabe G, Imamura M. Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology 1999; 57: 311-7.
4. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 2002; 98: 415-8.
5. Li YJ, Wei ZM, Meng YX, Ji XR. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol 2005; 11: 2117-23.
6. Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu KH. beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 2003; 88: 363-8.
7. Sui L, Tokuda M, Ohno M, Hatase O, Hando T. The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol 1999; 73: 202-9.
8. Bhagat R, Premalata CS, Shilpa V, Pallavi VR, Ramesh G, Vijay CR, Krishnamoorthy L. Altered expression of beta-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma. Tumour Biol 2013 Aug; 34: 2459-68.
9. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira VM, Lopes CS. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol 2004; 35: 663-9.
10. Chou YY, Jeng YM, Kao HL, Chen T, Mao TL, Lin MC. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology 2003; 43: 151-6.
11. Ju GZ, Wang XM, Fu SB, Liu SZ. Effect of ionizing radiation on the expression of p16, cyclinD1 and CDK4 in mouse thymocytes and splenocytes. Biomed Environ Sci 2003; 16: 47-52.
12. Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 1998; 32: 69-80.
13. Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Expression of E-cadherin and alpha- and beta-catenin mRNAs in ovarian cancers. Cancer Lett 1997; 115: 207-12.
14. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000; 97: 4262-6.
15. Hashimoto T, Yanaihara N, Okamoto A, Nikaido T, Saito M, Takakura S, Yasuda M, Sasaki H, Ochiai K, Tanaka T. Cyclin D1 predicts the prognosis of advanced serous ovarian cancer. Exp Ther Med 2011; 2: 213-9.
16. Chay WY, Chew SH, Ong WS, Busmanis I, Li X, Thung S, Ngo L, Lim SL, Lim YK, Chia YN, Koh E, Pang C, Soh LT, Wang J, Ho TH, Tay SK, Lim-Tan SK, Lim KH, Chia JW, Goh LK. HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One 2013; 8: e61565.
17. McCaughan H, Um I, Langdon SP, Harrison DJ, Faratian D. HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis. J Clin Pathol 2012; 65: 670-1; author reply 1-2.
18. Han CP, Hsu JD, Yao CC, Lee MY, Ruan A, Tyan YS, Yang SF, Chiang H. HER2 gene amplification in primary mucinous ovarian cancer: a potential therapeutic target. Histopathology 2010; 57: 763-4.
19. Ramieri MT, Murari R, Botti C, Pica E, Zotti G, Alo PL. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. Anticancer Res 2010; 30: 1287-92.
20. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, Camilleri-Broët S. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2007; 2: e1138.
21. Steffensen KD, Waldstrom M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A. The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17: 798-807.
22. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, Rubagotti A, Ragni N, Boccardo F. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005; 68: 154-61.
23. Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, Hidaka T, Sakai M, Saito S. HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res 2002; 93: 1250-7.
24. Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, Putti T, Salto-Tellez M, Lim GS. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol 2011; 64: 1097-101.